Serum albumin Antibodies

Serum albumin (ALB)

Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its principal function is the regulation of the colloidal osmotic pressure of blood.

Major zinc transporter in plasma, typically binds about 80 percent of all plasma zinc. .

Gene Information

Human
Gene Name:	ALB
Uniprot:	P02768
Entrez:	213

Family

Belongs to:
ALB/AFP/VDB family

Alternative Names

ALB; Albumin; cell growth inhibiting protein 42; DKFZp779N1935; growth-inhibiting protein 20; PRO0883; PRO0903; PRO1341; serum albumin

Molecular Weight

Mass (kDA):
69.367 kDA

Genomic Context

Human
Location:	4q13.3
Sequence:	4; NC_000004.12 (73404287..73421482)

Tissue Specificity

Plasma.

Subcellular Localizations

Secreted.

Diseases

• Kidney Diseases
• Malignant Neoplasms
• Neoplasms
• Hepatitis
• Liver Cirrhosis
• Fibrosis
• Inflammation
• Liver Carcinoma
• Carcinoma
• Liver Diseases
• Proteinuria Of Undiagnosed Cause
• Malnutrition
• Liver Neoplasms

• Kidney Failure, Chronic
• Hepatic Fibrosis
• Diabetes Mellitus
• Hepatitis B
• Kidney Failure
• Edema
• Hypertensive Disease

Interacting Proteins

• TFRC

Pathways

• Excretion
• Glomerular Filtration
• Secretion
• Pathogenesis
• Transport
• Coagulation
• Regeneration
• Localization
• Cell Differentiation
• Inflammatory Response
• Cell Proliferation
• Cell Growth
• Aging

• Liver Regeneration
• Liver Development
• Cell Adhesion
• Transdifferentiation
• Blood Coagulation
• Hepatocyte Differentiation
• Translation

PTMs

• Phosphorylation
• Cleavage
• Glycosylation
• Oxidation
• Methylation
• Nitration
• Reduction
• Hydroxylation

• Demethylation
• Carboxylation
• Nitrosylation
• Bromination
• Cysteinylation
• Ubiquitination
• Biotinylation
• Deacetylation

Research Areas

• Apoptosis
• Cancer
• Golgi Apparatus Markers
• Stem Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ALB

Boster Bio - Best Uses Of The ALB Marker

If you are looking for a new antibody, there are many reasons to choose the ALB Marker from Boster Bio. Boster Bio has done a fantastic job validating this monoclonal anti-mouse antibody. Each antibody is validated across multiple platforms with known negative and positive samples to ensure high affinity and specificity. The company also offers product credits to its first reviewers. The company is committed worldwide to finding the best antibodies.

Boster Bio NGF markers mimic human 2.5S S NGF.

Nerve growth factor, a neurotrophic peptide, is involved in the regulation and stimulation of target neurons in the central nervous system. It has a 97% affinity with its receptor, allowing researchers and clinicians to examine the differentiation of NGFNSCs from DPSCs. This review examines both the benefits and the potential impact of this NGF indicator on clinical trials.

Boster Bio's NGF markers are derived from human and rat tissues and contain 120 amino acids linked together in a polypeptide chain. They are stable for up to a year at -20degC. They are available as drop-on-demand and cross-validated with positive and negative samples. You can order them now to determine if your NGF marker is accurate.

A quality ELISA test kit is essential to a successful immunoassay. Boster Bio's NGF Markers are dimers of human 2.5S NGF. They were validated using a biologically relevant matrix. It is crucial to use high-quality ELISA tools for a successful immunoassay. Boster Bio has the ELISA kit that contains all of the information necessary to run a successful research. These kits include technical support as well as validation images. Boster Bio products are used worldwide by researchers. They have been cited over 29,000x.

The BDDA degrading bacteria not just removed the protein encoding this enzyme but also two benzalkonium chlorides (BDDA & BDTA), a precursor for human somatotrophic element. The BDDA bacteria that degraded the enzyme used sup 14C-labeled BDDA. This was then mineralized into COsub 2.

The NGF receptor is a transmembrane receptor and participates in central autonomic function. It also plays a role in the activity and regulation of the stress axis, which regulates the neurons' response to different stimuli. It is also important in the regeneration of nerve cells. All these factors make it an important part of maintaining our nervous system.

Boster Bio's anti ADAMTS13 antibody is a reliable predictor for relapse among people with ADAMTS13 deficiencies.

The current study looked at the role of ADAMTS13 IgG as a reliable predictor for relapse in patients with ADAMTS13 deficiencies. The study suggests that a lower anti ADAMTS13 IgG level could be a useful indicator in predicting relapse among people with this condition. Patients who have received unsuccessful treatment could have relapses if they have a higher level.

After mixing with normal human serum or plasma, the anti-ADAMTS13 antibodies were detected in 98 percent patient samples. The ratio of anti-ADAMTS13 antibody IgG from patients to the activity of ADAMTS13 was used to determine the inhibitory activity. The greater the anti-ADAMTS13 antibody antibody concentration, the greater its inhibitory ability.

Patients with severe ADAMTS13 impairment are at higher risk of relapse that patients with minimal or zero ADAMTS13 activities. The anti-ADAMTS13 antibody is associated with a higher prevalence of thrombotic thrombocytopenic purpura than with patients with normal levels of ADAMTS13 activity. Patients with severe ADAMTS13 deficiencies have a threefold higher risk of relapse. People with thrombotic thrombocytopenicpurpura were also found to have a high likelihood of relapse if they have an anti-ADAMTS13 antibodies.

The study showed that the anti-ADAMTS13 antibody was a reliable predictor of relapse in people suffering from adenoma from ADAMTS13 deficience. Although the antibody isn't clinically useful it can be used as a diagnostic tool in detecting relapse for people with ADAMTS13.

The anti-ADAMTS13 antibody was also associated with a high rate of miscarriage in women with systemic autoimmune diseases. The anti-ADAMTS13 antigen was found to increase miscarriage risk in women with autoimmune TTP. In a separate study of women suffering from gravid TTP, the prevalence of anti-ADAMTS13 antibodies was found to be significantly higher in women with a first trimester miscarriage than in patients with a later trimester relapse.

The anti-ADAMTS13 antibody was highly sensitive and accurate in predicting relapse among people with ADAMTS13 dysfunction. Patients with early-stage relapse and advanced stage disease both have antibodies to ADAMTS13. People suffering from ADAMTS13 Deficiency have been found to have reliable predictors of relapse if they have antibodies that are against this protein.

Boster Bio's anti ADAMTS13 antibody is a primary antigen

The study's design was to identify immunological properties antiADAMTS13 IgG antibodies in different disease stages. This method involved testing 101 samples of a broad range of patients. Each stage showed that anti-ADAMTS13 IgG was predominant in the majority of samples (n = 71), and only two cases had IgG2 antibodies.

Boster Bio's anti ADAMTTS13 anti-ADAMTTS13 antibodies reacted with Humans using flow cytometry and ELISA. All antibodies are tested for positive results by Boster Bio. It is used to predict the likelihood that patients suffering from ADAMTS13 deficiencies will relapse. The ADAMTS13 molecule belonged to the thrombospondin-1 disintegrin family. ADAMTS13 acts as a marker of disease and as a key distinguisher between different conditions. ADAMTS13 can be adversely affected by various types of inflammation and illnesses.

Anti-ADAMTS13 antibody is designed to detect high levels of ADAMTS13 activity. Its activity was determined using patient samples and normal human serum or citrated plasma. The greater the inhibitory activity, the lower the IgG activity. This antibody was chosen for further investigation. A secondary antibody against ALB was also developed by the company.

This study shows that the immune response against ADAMTS13 evolves over time. TTP has an antibody response that reflects the evolution in anti-ADAMTS13 antibody. It is important not to forget that anti ADAMTS13 antibodies are often polyclonal. This indicates that patients with TTP have antibodies that come from multiple subclasses.

The primary antibody to the ALB marker, ADAMTS13 was positive for predicting TTP recurrence. Patients with recurrent TTP had lower anti-ADAMTS13 activity than patients with stable disease. This result is consistent in previous studies on ADAMTS13's role in heart disease prevention.

ADAMTS13 gene is found in the liver's stellate cells. Infections with this gene are associated with severe sepsis, a non-infectious systemic inflammatory response syndrome, and hemolytic anemia. Patients with this gene defect may benefit from proper treatment and follow-up.

Boster Bio HLA A ELSA compatible with HLA A*0201

This study demonstrates the compatibility of Boster Bio’s HLA/A*0201 ELSA with human HLA/A*0201. The test was done using a T2 cell-line and 50 nmol/l a lipidated, pp65 peptide. The cells were then incubated in serum-free RPMI1640 medium with a peptide, one mmol/l of human b2-microglobulin, and incubated with the peptide. Tissue RNA was isolated and used as a template for reverse transcription and cDNA synthesis. The target sequence, the HLA-A*0201 S segment, was detected using a SYBR real-time quantitative PCR kit and the mouse GAPDH primer, 5'-AGGCGTAG

High-resolution DNA typing is compatible with HLA-A*0201. The haplotypes can be correlated very well. The haplotypes were also compatible with one another in the population. The results from this study are encouraging because they provide a better understanding of how common HLA-A haplotypes affect the ability to match solid organs and bone marrow allografts.

Boster Bio's HLA A*0201 ELSA compatible with HLA -B*0201 & B*0201. The HTNV NP derived FA9 peptide binds well to HLA A*0201 molecules. This study also found that the HTNV NP NP peptide could be used in conjunction with HLA-A*0201.

The boster Bio HLA-A ELSA is compatible for both HLA-A*0201 and B*0201. The recombinant L. monocytogenes gene (KBMA) was used to induce HLA-A*0201-restricted CD8+ T cell responses. The recombinant L. monocytogenes gene (BMA Lm Ag) was used to stimulate T cell responses to autologous or mismatched EBVLCL.

The peptide is compatible with the HLA-A*0201 antigen. A nonamer, peptide containing HLA0201 motif was synthesized. It was tested in transgenic mice. A nonamer protein derived from HCMVpp65 was tested for compatibility with a TAP+ cell line.

Although the GV9 peptide and FA9 peptide share similar amino-acid sequences, FA9 binds to HLAA*0201 more tightly. Both peptides have similar conformations, which results in a low RMSD (RMSD), of 0.415 A. The alignment of FA9 with GV9 reveals that they share the same conformation and both share Ala2 and Val2 primary anchor residues.